http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022512542-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01076 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-34 |
| filingDate | 2019-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022512542-A |
| titleOfInvention | Enzyme assay to quantify treatment in subjects with mucopolysaccharidosis type I or II |
| abstract | Enzyme assays for assessing in vivo therapy for MPS II (Hunter) or MPS I (Harler) subjects are described herein. Compositions and methods for assessing in vivo therapy in MPS I or II patients are disclosed herein. The assays described herein are very much incorporated by incorporating the recombinant enzyme as an additional reference standard, along with a quality control sample covering the entire range of quantification, to monitor assay performance. It provides a sensitive, quantitative, well-controlled enzyme activity assay, which provides a quantifiable assay for assessing in vivo therapies not provided by available assays. |
| priorityDate | 2018-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465855929 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164044170 |
Total number of triples: 16.